You searched for "VEGF"

210 results found

Initiatives in macular service provision

A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...

How many injections in nAMD: ranibizumab vs. aflibercept

Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...

ANGPTL-4 inhibition reduces inflammation in diabetic retinopathy

Diabetic retinopathy (DR) is the most common cause of blindness in working-age humans, and numbers are rising due to increased cases of type 2 diabetes (T2D). T2D is associated with increased obesity and dyslipidaemia, which is a major risk factor...

Intravitreal functional plasminogen in branch retinal vein occlusion

Branch retinal vein occlusion (BRVO) is the second most common vascular disorder of the eye. Intravitreal injections of anti-VEGF agents and corticosteroids have proven efficacy. Posterior vitreous cortex (PVC) adhesion has been shown to support the development of retinal vein...

International variations in ROP treatment

A retrospective cohort review of 48,087 premature infants weighing <1500 gm between 24 to 27 weeks gestation, from 11 high income countries in Australia, New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK . By...

Effect of single intravitreal injection of bevacizumab on contrast sensitivity in patients with central retinal vein occlusion

Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy. There are many studies reporting the efficacy of intravitreal anti-VEGF injections for macular oedema secondary to retinal vein occlusions. This paper looks at the contrast...

The global burden of age-related macular degeneration

Age-related macular degeneration (AMD) is the third leading cause of blindness (behind cataract and refractive error). The authors present the results of the Global Burden of Disease (GBD) 2015 study, which included 195 countries. The disability-adjusted life years (DALY) due...

FA findings in treatment-naive premature infants

This retrospective study examined fluorescein angiography (FA) images of 162 eyes of 81 treatment-naive infants with retinal vascular immaturity and persistent avascular retina (PAR) despite exceeding postmenstrual age of 60 weeks. Disc diameter (DD), optic disc-to-fovea distance (FD), the length...

Long-term treatment for diabetic macular oedema

The authors set out to characterise anti-VEGF treatment patterns and long-term outcomes in patients with diabetic macular oedema. A retrospective analysis of over 190 thousand patients on the Intelligent Research in Sight registry was performed. Of these, 1236 eyes have...

Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference

Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...

Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress

Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...